131 related articles for article (PubMed ID: 38282338)
21. From cancer stem cells to tumor maintenance in melanoma.
Fukunaga-Kalabis M; Roesch A; Herlyn M
J Invest Dermatol; 2011 Aug; 131(8):1600-4. PubMed ID: 21654838
[TBL] [Abstract][Full Text] [Related]
22. Models and mechanisms in malignant melanoma.
Benjamin CL; Melnikova VO; Ananthaswamy HN
Mol Carcinog; 2007 Aug; 46(8):671-8. PubMed ID: 17570501
[TBL] [Abstract][Full Text] [Related]
23. Balloon cell melanoma possessed the ability to develop BRAF V600E mutation in cancer cells.
Chen YY; Lan CE; Yen MC; Cheng ST
Kaohsiung J Med Sci; 2021 Feb; 37(2):154-155. PubMed ID: 33118306
[No Abstract] [Full Text] [Related]
24. Inhibition of the stem cell marker nestin reduces tumor growth and invasion of malignant melanoma.
Akiyama M; Matsuda Y; Ishiwata T; Naito Z; Kawana S
J Invest Dermatol; 2013 May; 133(5):1384-7. PubMed ID: 23389394
[No Abstract] [Full Text] [Related]
25. Usefulness of immunocytochemistry for the detection of the BRAF(V600E) mutation in circulating tumor cells from metastatic melanoma patients.
Hofman V; Ilie M; Long-Mira E; Giacchero D; Butori C; Dadone B; Selva E; Tanga V; Passeron T; Poissonnet G; Emile JF; Lacour JP; Bahadoran P; Hofman P
J Invest Dermatol; 2013 May; 133(5):1378-81. PubMed ID: 23303445
[No Abstract] [Full Text] [Related]
26. Re: Determinants of BRAF mutations in primary melanomas.
Purdue MP
J Natl Cancer Inst; 2005 Mar; 97(5):401-2; author reply 402. PubMed ID: 15741578
[No Abstract] [Full Text] [Related]
27. Progression of NRAS and BRAF mutations in cutaneous melanoma.
Rosso R; Romagosa Y; Kirsner RS
J Invest Dermatol; 2009 Jun; 129(6):1318. PubMed ID: 19434085
[No Abstract] [Full Text] [Related]
28. Primary Noncutaneous Malignant Melanoma of the Breast.
Rassouli M; Voutsadakis IA
Breast J; 2016 Nov; 22(6):688-691. PubMed ID: 27488963
[TBL] [Abstract][Full Text] [Related]
29. Pseudovitelliform maculopathy secondary to BRAF and MEK inhibitors in a patient with metastasic melanoma.
Alba-Linero C; Rocha De Lossada C; Delgado-Fernández AS; Jódar-Márquez M; Rodríguez Calvo De Mora M; Berciano-Guerrero MA
J Biol Regul Homeost Agents; 2019 September-October,; 33(5):1497-1500. PubMed ID: 31583878
[No Abstract] [Full Text] [Related]
30. Combining a BCL2 inhibitor with the retinoid derivative fenretinide targets melanoma cells including melanoma initiating cells.
Mukherjee N; Reuland SN; Lu Y; Luo Y; Lambert K; Fujita M; Robinson WA; Robinson SE; Norris DA; Shellman YG
J Invest Dermatol; 2015 Mar; 135(3):842-850. PubMed ID: 25350317
[TBL] [Abstract][Full Text] [Related]
31. Advances in the treatment of late stage melanoma.
Walkington LA; Lorigan P; Danson SJ
BMJ; 2013 Mar; 346():f1265. PubMed ID: 23460638
[No Abstract] [Full Text] [Related]
32. Oncogenic B-RAF(V600E) signaling induces the T-Box3 transcriptional repressor to repress E-cadherin and enhance melanoma cell invasion.
Boyd SC; Mijatov B; Pupo GM; Tran SL; Gowrishankar K; Shaw HM; Goding CR; Scolyer RA; Mann GJ; Kefford RF; Rizos H; Becker TM
J Invest Dermatol; 2013 May; 133(5):1269-77. PubMed ID: 23190890
[TBL] [Abstract][Full Text] [Related]
33. Melanoma stem cells.
Roesch A
J Dtsch Dermatol Ges; 2015 Feb; 13(2):118-24. PubMed ID: 25631128
[TBL] [Abstract][Full Text] [Related]
34. Malignant melanoma, papillary thyroid carcinoma and Erdheim-Chester disease, associated with both BRAF
Papanikolaou M; Chohan T; Millington GWM
Clin Exp Dermatol; 2020 Jun; 45(4):512-514. PubMed ID: 31875997
[No Abstract] [Full Text] [Related]
35. Cancer Stem Cells (CSCs) in melanoma: There's smoke, but is there fire?
Brinckerhoff CE
J Cell Physiol; 2017 Oct; 232(10):2674-2678. PubMed ID: 28078710
[TBL] [Abstract][Full Text] [Related]
36. Distinctive clinical and dermoscopic features of BRAF V600K mutated melanomas.
Ponti G; Manfredini M; Tomasi A; Pellacani G
Br J Dermatol; 2015; 172(5):1438-40. PubMed ID: 25323827
[No Abstract] [Full Text] [Related]
37. Neratinib kills B-RAF V600E melanoma via ROS-dependent autophagosome formation and death receptor signaling.
Dent P; Booth L; Poklepovic A; Kirkwood JM
Pigment Cell Melanoma Res; 2022 Jan; 35(1):66-77. PubMed ID: 34482636
[TBL] [Abstract][Full Text] [Related]
38. Association between the germline MC1R variants and somatic BRAF/NRAS mutations in melanoma tumors.
Scherer D; Rachakonda PS; Angelini S; Mehnert F; Sucker A; Egberts F; Hauschild A; Hemminki K; Schadendorf D; Kumar R
J Invest Dermatol; 2010 Dec; 130(12):2844-8. PubMed ID: 20720566
[No Abstract] [Full Text] [Related]
39. Increased expression of stem cell markers in malignant melanoma.
Klein WM; Wu BP; Zhao S; Wu H; Klein-Szanto AJ; Tahan SR
Mod Pathol; 2007 Jan; 20(1):102-7. PubMed ID: 17143262
[TBL] [Abstract][Full Text] [Related]
40. Development of five new melanoma low passage cell lines representing the clinical and genetic profile of their tumors of origin.
de Miera EV; Friedman EB; Greenwald HS; Perle MA; Osman I
Pigment Cell Melanoma Res; 2012 May; 25(3):395-7. PubMed ID: 22404973
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
